Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 602
Filter
1.
Article | IMSEAR | ID: sea-239305

ABSTRACT

Background: Bronchial asthma, a hypersensitivity illness, is rising quickly in the modern world, particularly in wealthy nations. However, according to clinical features, bronchial asthma and Ayurvedic Tamaka Shwasa are similar diseases. Asthma is incurable, according to traditional medical knowledge. Both patients and doctors are looking at complementary and alternative systems of medicine as options because current prescriptions do not offer adequate treatment for terminal and long-term cures. Ayurvedic medicine has the potential to be a viable and efficient treatment option for bronchial asthma. Vaman karma is helpful for treatment globally so that people worldwide can keep faith in it based on scientific evidence. The first line of treatment for Tamakshwasa’s Utkleshita vastha is Vamana. To determine Vamana Karma’s involvement in Tamak shwas, a season it connected to Tamak shwasa has been searched for and attempted to be established in this case study. Purpose: This study aimed to assess the efficacy of Ayurvedic management, including specific Ishwaku vaman karma, in Tamaka Shwasa. Materials and Methods: A single case study of a 21-year-old man diagnosed with bronchial asthma. He was presented with frequent allergy due to dust, had an onset of sneezing due to cold weather, had a complaint of cold and cough on and off since childhood, and had a history of pneumonia in childhood. Observation and Outcome: A 9-day symptomatic patient assessment was completed. The patient’s overall quality of life was greatly enhanced, and the outcome was satisfactory. In conclusion, the above-mentioned regimen significantly improved the management of bronchial asthma.

2.
J Indian Med Assoc ; 2024 Jul; 122(7): 70-75
Article | IMSEAR | ID: sea-238895

ABSTRACT

Background : A large proportion of patients prescribed inhaled medications do not use their inhalers correctly. Hence in this backdrop, our study was done to assess the level of knowledge about the condition as well as skills for using inhaler devices. Materials and Methods : It was a cross-sectional study with consecutive 80 eligible patients diagnosed either with asthma or COPD, were recruited after taking informed consent and their skill and inhaler use technique was captured in data collection form. Knowledge about the disease the patient was suffering was assessed using pre- structured questionnaire and expressed as percentage of patients of asthma or COPD, answering the questions positive or negative. Skills pertaining to self-management were checked using structured checklist (taking reference from previous studies and guidelines and modified) and asking the patient to demonstrate the technique of using inhalational medication. The total score obtained by summing up scores for different steps were named as Device Appropriateness Index (DAI). Results : Certain steps in proper device technique were commonly omitted. Among MDI users, the steps least often optimally completed were exhalation to residual volume prior to putting the inhaler in the mouth (46.16%), shaking the device before use (41.03%) and holding the breath for 5-10s after removal of the inhaler (33.33%). Among DPI users, the steps least often completed were exhalation to residual volume prior to putting the inhaler in the mouth (44.44%), to inhale forcefully and deeply from the inhaler (37.04%) and holding the breath for 5-10s after removal of the inhaler (29.63%). Conclusion : The inappropriate use of inhalers and knowledge about their own conditions can lead to suboptimal adherence, poor clinical control, dissatisfaction and consequently high economic burden in patients suffering from asthma and COPD. The misuse of inhalers has been an important roadblock to both patients and clinicians for years.

3.
Article | IMSEAR | ID: sea-240033

ABSTRACT

Background: Non-responding to standard doses of inhalational corticosteroids (ICS) remains a challenge in the management of asthma, requiring add-on therapy. Acebrophylline, a theophylline derivative, with multiple mechanisms of action and properties, could work as a suitable alternative to montelukast as an add-on therapy. Aims and Objectives: The aim of this study was to compare the efficacy and safety of montelukast versus acebrophylline as an add-on therapy to ICS in the treatment of bronchial asthma. Materials and Methods: One hundred bronchial asthma patients, fulfilling inclusion/exclusion criteria, were enrolled and randomized in a 1:1 ratio into two groups of 50 each to receive either oral montelukast 10 mg OD or oral acebrophylline 200 mg OD with budesonide. Inhaled salbutamol was permitted as rescue medication during acute exacerbations. Primary outcome measures were change in pulmonary function test (PFT) parameters and asthma control questionnaire (ACQ) scores at baseline and 12 weeks. Adverse events, if any were recorded. Results: There was a statistically significant difference in the improvement of mean PFT parameters at the end of 12 weeks in the montelukast group (P < 0.001), but not in acebrophylline group (P = 0.253). Montelukast was more efficacious than acebrophylline in improving PFT parameters at 6 and 12 weeks. Both treatment modalities significantly improved ACQ score at 12 weeks (P < 0.001), the difference between two groups was not statistically significant (1.4 ± 0.53 in Group A vs. 1.32 ± 0.44 in Group B, P = 0.436). No significant adverse effects were seen in both groups. Conclusion: Montelukast, with low-dose ICS, had better efficacy over acebrophylline. Both montelukast and acebrophylline improved the quality of life in mild-to-moderate persistent asthma patients by decreasing nocturnal symptoms and the need for rescue medications.

4.
Article | IMSEAR | ID: sea-240146

ABSTRACT

Background: The global burden of bronchial asthma is on the rise. Asthma is a disorder of airflow obstruction associated with deranged pulmonary functions and autonomic imbalance. Though past studies have shown the beneficial effects of various asanas and breathing exercises in bronchial asthma, the role of such non-pharmacological alternative modalities in reducing morbidity and financial burden in patients is far from clear. Aims and Objectives: To assess the effect of Pranayama techniques on pulmonary functions and heart rate variability parameters in bronchial asthma patients. Materials and Methods: In our present study, we have recruited patients with mild-to-moderate bronchial asthma after taking written and informed consent. These patients were then asked to perform three pranayama techniques, namely Suryanadi, Bhastrika, and Kapalabhati pranayama, for 30 min a day, 3 days a week, for up to 4 weeks. Pulmonary function test parameters (forced vital capacity [FVC], forced expiratory volume in 1st s [FEV1], FEV1/FVC, peak expiratory flow rate) and Autonomic function test parameters (Time domain: mean HR, mean RR, NN50, pNN50, SDNN; Frequency domain: very low frequency (LF), LF, LF/high frequency (HF) ratio, total power) were compared before and after the intervention using a paired t-test. Results: After the intervention, improvements were recorded in pulmonary functions. Furthermore, pranayama was found to cause a shift in the sympathovagal balance toward the parasympathetic system. However, the changes recorded were not statistically significant. This shows further research in this field is required with a larger sample size, which may yield statistically significant data. Conclusion: Thus, we conclude that pranayama can be a useful alternative therapy for reducing morbidity and mortality in bronchial asthma patients.

5.
J Ayurveda Integr Med ; 2024 Jan; 15(1): 1-5
Article | IMSEAR | ID: sea-236910

ABSTRACT

Ayurveda is a holistic science that treats root cause of diseases. One disease can become a causative factor for another disease. This concept is fundamentally described as Nidanarthakar Vyadhi in Ayurveda. In the same way, treating causative diseases is helpful in managing another diseases. However, many published clinical trials on Ayurveda management of Bronchial asthma and Hemorrhoids exist. There is a dearth of published case reports or clinical trials showing an association between Arsha (hemorrhoids) and Shwasa (bronchial asthma). This case report gives important viewpoints about the role of hemorrhoids and its treatment in pathogenesis and treatment of bronchial asthma. This case report of a 38-year-old female patient known case of bronchial asthma who came to the OPD of Kayachikitsa Government Ayurved College and Hospital, Nagpur with complaints of cough with sputum, breathlessness, chest pain (on/off) for three years. The severity of these symptoms increased for three months. The patient was treated with conventional Shwasghna Chikitsa (treatment of bronchial asthma) for five days, but the response was unsatisfactory. After five days of Shwasghna treatment, the patient gave a history of hemor- rhoids. Considering Nidanarthakar Roga (one disease can cause of another disease), treatment was planned. The treatment principle is the treatment of causative disease (Arsha). Hence, Arshoghna treatment was added. Sig- nificant increases in peak expiratory flow rate (PEFR), Sustained minimal inspiration (SMI), and Modified Medical Research Council Dyspnoea scale (mMRC) were observed. The respiratory rate was also reduced from 28/min to 18/min. Improvement in the subjective and objective parameters of the patient was observed. The inclusion of Arsha treatment can be helpful in the management of Tamakshwas (Bronchial Asthma). The need for further research in this direction is warranted.

6.
Article in Chinese | WPRIM | ID: wpr-1017805

ABSTRACT

Objective To investigate the effect of eosinophil(EOS)/neutrophil(NER)in peripheral blood on asthma recurrence in children with bronchial asthma(BA)after treatment.Methods A prospective cohort study was conducted in the study.BA children admitted to the hospital from February 2020 to February 2022 were selected as the research objects.All children were treated regularly and their condition was under con-trol.After a follow-up of 6 months,the recurrence of the children was recorded.EOS/NER,interleukin(IL)-4 and IL-5 of children with and without relapse before treatment and at 1 week of treatment were compared.Lo-gistic regression analysis model was established to test the effect of EOS/NER on the recurrence of asthma in children with BA after treatment.The receiver operating characteristic(ROC)curve was drawn to analyze the predictive value of EOS/NER,IL-4 and IL-5 before treatment for the recurrence risk of BA children after treatment.Results A total of 128 children with BA were included.25 cases recurred after 6 months of follow-up,with a recurrence rate of 19.53%.EOS/NER,IL-4 and IL-5 of BA children after 1 week of treatment were lower than those before treatment(P<0.05).EOS/NER,IL-4 and IL-5 of recurrent children before treat-ment and 1 week after treatment were higher than those of non-recurrent children(P<0.05).There were no statistically significant differences in EOS/NER,IL-4,IL-5 levels between children of different genders,age groups,and treatment regimens before and after 1 week of treatment(P>0.05).Increased EOS/NER,in-creased level of IL-4 and increased level of IL-5 had effect on the recurrence of BA children after treatment and may be risk factors for recurrence(OR>1,P<0.05).The ROC curve showed that area under the curve of EOS/NER before treatment for predicting the recurrence was 0.810(95%CI:0.724-0.896,P<0.001)in BA patients after 6 months of treatment,with moderate predictive value.Conclusion EOS/NER before treat-ment in BA children may be an independent risk factor for recurrence after treatment,and has moderate pre-dictive value for recurrence risk.

7.
Article in Chinese | WPRIM | ID: wpr-1017808

ABSTRACT

Objective To investigate the relationship between serum endothelial cell specific 1(endocan),deception receptor 3(DcR3),airway inflammation and clinical efficacy in children with bronchial asthma.Methods A total of 171 children with bronchial asthma who were admitted to the hospital from June 2020 to June 2022 were selected as the observation group,and 80 healthy children who underwent physical examina-tion in the hospital during the same period were selected as the control group.The levels of serum endocan,DcR3 levels and exhaled nitric oxide(FeNO)in the two groups were compared,and the correlation between the serum endocan,DcR3 levels and FeNO level in the observation group was analyzed.The levels of serum endocan and DcR3 were compared after individualized glucocorticoid treatment.The related factors affecting the clinical efficacy of the children were analyzed by univariate and multivariate Logistic regression analysis.Results The levels of serum endocan,DcR3 and FeNO in the observation group were higher than those in the control group(P<0.05).There was positive correlation between the levels of serum endocan,DcR3 and Fe-NO in the observation group(r=0.569,0.398,P<0.05).After treatment,the levels of serum endocan,DcR3 and FeNO in the observation group were lower than those before treatment(P<0.05).After treatment,there were 140 cases of children in the effective group,and 31 cases of children in the ineffective group.Univariate a-nalysis showed that there were statistical differences between the effective group and the ineffective group in the severity of disease,allergy history,endocan,DcR3 and FeNO levels(P<0.05).Multivariate Logistic re-gression analysis showed that severity of disease,allergy history,elevated serum levels of endocan and DcR3 were all independent risk factors affecting the clinical efficacy of children(P<0.05).Conclusion The levels of serum endocan and DcR3 are significantly related with airway inflammation in children with bronchial asth-ma,and their abnormally high levels could affect the clinical efficacy of glucocorticoid treatment in children with bronchial asthma.

8.
Article in Chinese | WPRIM | ID: wpr-1017832

ABSTRACT

Objective To analyze the relationship between serum long chain non coding ribonucleic acid(ln-cRNA)ANRIL,microRNA(miR)-423-5p and airway inflammation and remodeling in children with bronchial asthma and its predictive value.Methods A total of 98 children with bronchial asthma treated in Haikou Ma-ternal and Child Health Hospital from June 2020 to December 2022 were selected.46 children with acute at-tack were selected as the attack group and 52 children with clinical remission were selected as the remission group.Another 50 children who were healthy during physical examination in the same period were selected as the health group.The relative expression levels of serum lncRNA ANRIL and miR-423-5p were detected by real-time fluorescence quantitative polymerase chain reaction.The serum inflammatory factor indicators[in-terleukin-13(IL-13),transforming growth factor-β1(TGF-β1),vascular endothelial growth factor(VEGF)]were detected by enzyme-linked immunosorbent assay.Airway remodeling indicators[bronchial thickness(T/D),pipe wall area/total cross-sectional area of gas pipeline(WA)]and lung function indicators[first second forced expiratory volume(FEV1),peak expiratory flow(PEF),maximum mid expiratory flow(MMEF)]were measured.The correlation between expression of serum lncRNA ANRIL,miR-423-5p and airway inflam-mation and remodeling indicators were analyzed by the Pearson method.The predictive value of serum ln-cRNA ANRIL and miR-423-5p in the diagnosis of bronchial asthma was analyzed by receiver operating charac-teristic(ROC)curve.Results The relative expression level of serum lncRNA ANRIL in remission and attack groups was higher than that in healthy group,and the relative expression level of serum miR-423-5p was lower than that in healthy group,with statistical significance(P<0.05).The relative expression level of serum ln-cRNA ANRIL in the attack group was higher than that in the remission group,and the relative expression lev-el of serum miR-423-5p was lower than that in the remission group,with statistical significance(P<0.05).The levels of serum VEGF,IL-13 and TGF-β1 in attack and remission groups were higher than those in healthy group,and the difference was statistically significant(P<0.05).The levels of serum VEGF,IL-13 and TGF-β1 in attack group were higher than those in remission group,and the difference was statistically sig-nificant(P<0.05).The levels of T/D and WA in the remission and attack groups were higher than those in the healthy group,and the levels of FEV,,PEF and MMEF were lower than those in the healthy group,with statistical significance(P<0.05).The levels of T/D and WA in the attack group were higher than those in the remission group,and the levels of FEV1,PEF and MMEF were lower than those in the remission group,with statistical significance(P<0.05).The results of Pearson correlation analysis showed that serum ln-cRNA ANRIL expression was positively correlated with airway inflammation and remodeling indicators,and negatively correlated with lung function indicators(P<0.05).The expression of miR-423-5p was negatively correlated with airway inflammation and remodeling indexes,and positively correlated with lung function inde-xes(P<0.05).ROC curve analysis showed that the area under the curve of lncRNA ANRIL and miR-423-5p alone and combined detection were 0.772,0.707 and 0.865 respectively,the predictive value of combined de-tection in diagnosing bronchial asthma was higher.Conclusion The relative expression level of serum lncRNA ANRIL increase in children with bronchial asthma,and miR-423-5p decrease,which promote airway inflamma-tion,remodeling,lung function decrease,and which has high diagnostic efficacy for children with bronchial asthma.

9.
Article in Chinese | WPRIM | ID: wpr-1031423

ABSTRACT

This paper summarized the characteristics of constitution, disease, and syndrome of five different phenotypes of bronchial asthma including allergic asthma, cough variant asthma, chest tightness variant asthma, psychological stress asthma, and hormone-dependent asthma, and systematically expounds the application of three-dimensional diagnosis and treatment pattern, that is differentiation of constitution, disease and syndromes in the five phenotypes of bronchial asthma. It is considered that the allergic constitution is the main one of bronchial asthma, which is usually combined with the constitutions of qi-deficiency, yin-deficiency, yang-deficiency, qi-stagnation and others. In the treatment of bronchial asthma, constitution, disease and syndromes should all be taken into account but applied flexibly according to the order of the urgency and priority. The three-dimensional diagnosis and treatment pattern can reflect the essential characteristics and clinical panorama of bronchial asthma more comprehensively and objectively and provide effective intervention measures and management programs for the prevention and treatment by traditional Chinese medicine.

10.
China Modern Doctor ; (36): 70-73, 2024.
Article in Chinese | WPRIM | ID: wpr-1038106

ABSTRACT

Objective To observe the clinical efficacy of Sushen Jiubao decoction in the treatment of acute exacerbation of bronchial asthma and its effect on Th1/Th2 factors.Methods Ninety-eight patients with acute exacerbation of bronchial asthma treated in Sishengbianji Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University from February 2022 to May 2023 were selected and divided into treatment group and control group according to random number table method,with 49 cases in each group.The control group was given conventional treatment such as oxygen inhalation and atomization,and the treatment group was additionally treated with Sushen Jiubao decoctionon based on the treatment of control group.The clinical efficacy,TCM syndrome score,pulmonary function indicators[forced expiratory volume in first second(FEV1),peak expiratory flow(PEF)],and laboratory indicators[interleukin(IL)-4,IL-13,interferon-γ(IFN-γ),immunoglobulin E(IgE)].Results The total effective rate of treatment group was significantly higher than that of control group(χ2=9.287,P=0.010).After treatment,the TCM syndrome scores,serum IL-4,IL-13 and IgE levels of two groups were significantly lower than before treatment,and FEV1,PEF and IFN-γ were significantly higher than before treatment(P<0.05).The TCM syndrome score,serum IL-4,IL-13 and IgE levels in treatment group were significantly lower than those in control group,and FEV1,PEF and IFN-γ were significantly higher than those in control group(P<0.05).Conclusion Sushen Jiubao decoction can significantly improve clinical efficacy,reduce the level of inflammatory factors,and improve pulmonary function in the treatment of acute exacerbation of bronchial asthma.

11.
Article in Chinese | WPRIM | ID: wpr-1005372

ABSTRACT

ObjectiveTo investigate the possible mechanism of Guben Fangxiao Beverage (固本防哮饮) for the prevention and treatment of chronic airway inflammation during asthma remission. MethodsThirty-six female Balb/c mice were randomly divided into normal group, model group, low-, medium-, and high-dose of Guben Fangxiao Beverage group and montelukast sodium group, with 6 mice in each group. Except for the normal group, ovalbumin and respiratory syncytial virus were used in other groups to establish a mouse model of bronchial asthma in remission stage. After molding, the low-, medium-, and high-dose groups of Guben Fangxiao Beverage were respectively given 12, 24, and 36 g/(kg·d), the montelukast sodium group was given montelukast sodium granule 2.6 mg/(kg·d), and the mice in the normal group and model group were given 20 ml of double-distilled water, all by gavage, once a day for 28 days. The levels of interleukin 4 (IL-4) and interleukin 5 (IL-5) in the lung tissue of mice were detected; HE staining was used to observe the pathology of the lung tissue and to score the inflammation; DHE staining was used to observe the level of reactive oxygen species (ROS) in the lung tissue, and the activities of mitochondrial respiratory chain complexes Ⅰ, Ⅱ, Ⅲ, Ⅳ, and Ⅴ in the lung tissue were detected; the levels of serum superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA) and adenosine triphosphate (ATP) were detected; the protein expression levels of phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK), nuclear factor erythroid 2-related factor 2 (Nrf2), haem oxygenase 1 (HO-1) and cAMP responsive element binding protein (CREB) in the lung tissues of the model group were detected by Western blot. ResultsCompared with the normal group, the histopathological results of the lungs of mice in the model group showed an increase in inflammatory cells around the airways and an increase in inflammatory score; DHE staining showed an increase in the level of ROS, and an increase in the levels of IL-4 and IL-5 in the lung tissues; the levels of serum SOD, CAT, and ATP were reduced, and the level of MDA was elevated; the activities of the mitochondrial respiratory chain complexes Ⅰ, Ⅱ, Ⅲ, Ⅳ, and Ⅴ of the lung tissues were reduced, and the activities of p-AMPK, Nrf2, CREB protein expression decreased (P<0.05). Compared with the model group, the lung tissue inflammatory cells and inflammation scores of mice in each Guben Fangxiao Beverage dose group and montelukast sodium group were reduced; the levels of ROS, IL-4 and IL-5 in the lung tissue were reduced; the levels of CAT and ATP in the serum increased, and the content of MDA was reduced; and the activities of mitochondrial respiratory chain complexes Ⅰ and Ⅱ, as well as the expression of CREB protein, were elevated in the lung tissue (P<0.05). Compared with the high-dose group, the MDA level of the medium-dose Guben Fangxiao Beverage group decreased (P<0.05). The activity of mitochondrial respiratory chain complex V in the medium-dose group was higher than that in the montelukast sodium group, and the activity of mitochondrial respiratory chain complex Ⅳ in the medium- and high-dose groups was higher than that in the low-dose group (P<0.05). ConclusionGuben Fangxiao Beverage can inhibit oxidative stress and improve mitochondrial function to relieve chronic airway inflammation in bronchial asthma model mice during asthma remission, and its mechanism may be related to the activation of AMPK/Nrf2/HO-1 signaling pathway.

12.
Article in Chinese | WPRIM | ID: wpr-1028751

ABSTRACT

AIM To explore the mechanism of Yiqi Wenyang Huwei Decoction on airway inflammation improvement of rats with bronchial asthma based on IL-25/NF-κB signaling pathway.METHODS 60 rats were randomly divided into the control group,the model group,the dexamethasone group(0.2 mg/mL),the low-dose,medium-dose and high-dose Yiqi Wenyang Huwei Decoction groups(1,2,4 g/mL),with 10 rats in each group.Intraperitoneal injection of ovalbumin(OVA)and aluminum hydroxide suspension was applied to establish the rat asthma model,followed by 2-week corresponding dosing of the drugs.The rats of each group had their daily diet,mental status,hair growth and respiration observed;their differential count of inflammatory cells in bronchoalveolar lavage fluid(BALF)detected by automatic hematology analyzer;their pathological changes of lung tissue observed by HE staining;their pulmonary IL-25 protein expression detected by immunohistochemistry(IHC);their levels of IL-4,IL-5 and IL-13 in BALF measured by ELISA;their pulmonary expression of IL-25 and TRAF6 mRNA detected by RT-qPCR;and their pulmonary protein expressions of IL-25,TRAF6,IκBα,p-IκBα,NF-κB p65 and p-NF-κB p65 detected by Western blot.RESULTS Compared with the control group,the model group displayed severe damage of the lung tissue and infiltration of a large number of inflammatory cells;increased number of inflammatory cells and levels of IL-4,IL-5 and IL-13 in BALF(P<0.01);increased mRNA expressions of IL-25 and TRAF6,and pulmonary protein expressions of IL-25,TRAF6,p-IκBα/IκBα and p-NF-κB p65/NF-κB p65(P<0.01).Compared with the model group,all of the Yiqi Wenyang Huwei Decoction groups shared improved pulmonary infiltration of inflammatory cells;decreased number of inflammatory cells and levels of IL-4,IL-5 and IL-13 in BALF(P<0.05,P<0.01);and decreased mRNA expressions of IL-25 and TRAF6,and pulmonary protein expressions of IL-25,TRAF6,p-IκBα/IκBα and p-NF-κB p65/NF-κB p65(P<0.01).CONCLUSION Yiqi Wenyang Huwei Decoction can inhibit the airway inflammation in the rat model of bronchial asthma,which may be related to the inhibited activation of IL-25/NF-κB signaling pathway and the reduced expression of inflammatory factors.

13.
Article in English | WPRIM | ID: wpr-1012744

ABSTRACT

@#Introduction: Chronic non-communicable respiratory diseases (CNCRDs) encompass a group of conditions affecting the airways and lung structures, including Chronic Obstructive Pulmonary Disease (COPD), emphysema, allergic rhinitis, asthma, pulmonary arterial hypertension, and cystic fibrosis. CNCRDs pose a significant global health challenge, resulting in approximately four million deaths annually. This study aimed to identify the prevalence and risk factors associated with CNCRDs and measure trends in the prevalence of these risk factors over time. Methods: A cross-sectional epidemiological study was conducted using data collected from primary health centers on both sides of Mosul City. The study period extended from January 1 to July 31, 2022, with information obtained from (40) primary health centers, consisting of (20) centers on the right side and (20) centers on the left side of Mosul. Results: In 2021, the City of Mosul recorded a total of 13,005 registered cases, with 5,598 cases being attributed to asthma (43%), and 7,347 cases being associated with COPD (57%). Bronchial asthma constituted 43% of cases, with 5598 patients, and the highest incidence occurred in the age group between 20-44 years. Conclusion: The prevalence of bronchial asthma and COPD among patients with CNCRDs in Mosul is alarmingly high. It emphasizes the importance of implementing preventive policies and strategies targeting modifiable risk factors for these respiratory conditions.

14.
Chinese Pharmacological Bulletin ; (12): 363-371, 2024.
Article in Chinese | WPRIM | ID: wpr-1013585

ABSTRACT

Aim To anticipate the mechanism of zuka- mu granules (ZKMG) in the treatment of bronchial asthma, and to confirm the projected outcomes through in vivo tests via using network pharmacology and molecular docking technology. Methods The database was examined for ZKMG targets, active substances, and prospective targets for bronchial asthma. The protein protein interaction network diagram (PPI) and the medication component target network were created using ZKMG and the intersection targets of bronchial asthma. The Kyoto Encyclopedia of Genes and Genomics (KEGG) and gene ontology (GO) were used for enrichment analysis, and network pharmacology findings were used for molecular docking, ovalbumin (OVA) intraperitoneal injection was used to create a bronchial asthma model, and in vivo tests were used to confirm how ZKMG affected bronchial asthma. Results There were 176 key targets for ZKMG's treatment of bronchial asthma, most of which involved biological processes like signal transduction, negative regulation of apoptotic processes, and angiogenesis. ZKMG contained 194 potentially active components, including quercetin, kaempferol, luteolin, and other important components. Via signaling pathways such TNF, vascular endothelial growth factor A (VEGFA), cancer pathway, and MAPK, they had therapeutic effects on bronchial asthma. Conclusion Key components had strong binding activity with appropriate targets, according to molecular docking data. In vivo tests showed that ZKMG could reduce p-p38, p-ERKl/2, and p-I

15.
Clinics ; Clinics;79: 100385, 2024. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1564341

ABSTRACT

Abstract Objective To explore the relationship between Growth Hormone Insulin-like Growth Factors (GH-IGFs) and growth retardation in children with bronchial asthma. Methods 112 children with bronchial asthma and 50 healthy children were studied. Serum GH, IGF-1, and Insulin-like Growth Factor Binding Protein 3 (IGFBP3) were assessed by ELISA. GH-IGFs-related parameters were compared, and the correlation between the parameters and bronchial asthma severity was analyzed. The bronchial asthma group was divided into the growth retardation group and non-growth retardation group to analyze the diagnostic value of GH-IGFs in growth retardation and the relationship between GH-IGFs and growth retardation. Results GH, IGF-1, and IGFBP3 in the bronchial asthma group were lower. GH, IGF-1, and IGFBP3 levels were decreased with the severity of bronchial asthma. GH, IGF-1, and IGFBP3 in the growth retardation group were lower than those in the non-growth retardation group. The AUC of GH-IGFs combined detection was higher than that of GH and IGFBP3 alone detection. GH < 9.27 μg/L and IGF-1 < 179.53 mmoL/L were risk factors for growth retardation in patients with bronchial asthma. Conclusion GH-IGFs-related parameters have diagnostic value for growth retardation in children, and decreased levels of GH and IGF-1 are risk factors for growth retardation in children.

16.
Rev. habanera cienc. méd ; 22(6)dic. 2023.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1584003

ABSTRACT

Introducción: El término síndrome ha sido empleado indistintamente al de enfermedad, si corresponde a una sola entidad nosológica, en las discusiones diagnósticas y en algunos textos, en afecciones bronquiales: la bronquitis aguda y crónica, la bronquiectasia y, en especial, el asma bronquial. Objetivo: Precisar el significado del síndrome bronquial y sus variantes en función del diagnóstico médico. Material y Métodos: Investigación cualitativa mediante revisión, en libros de Semiología y textos afines, del síndrome bronquial y de las principales afecciones en que se manifiesta. Resultados: Existe ambigüedad terminológica respecto al síndrome bronquial y sus variantes e, incluso, algunos libros no los contemplan entre los síndromes respiratorios. En algunos textos hay trastornos bronquiales definidos como síndromes y en otros como entidades nosológicas: las bronquitis, aguda y crónica, el asma bronquial y la bronquiectasia. Se propone el empleo del síndrome bronquial, el cual, de acuerdo con la etiopatogenia preponderante, exhibirá mayor especificidad diagnóstica en dos grandes sub-síndromes: el bronquítico y el bronquial obstructivo. Conclusiones: El síndrome bronquial expresa una afección del árbol bronquial con dos grandes sub-síndromes de mayor especificidad diagnóstica: el bronquítico (agudo o crónico) y el bronquial obstructivo, difuso (broncoespástico o broncoestenótico) o localizado. Tos y expectoración predominan en el primero y disnea, en el segundo; ambos con estertores roncos, sibilantes y subcrepitantes. Considerar síndrome o enfermedad el asma bronquial es cuestión de enfoque. Definir la bronquiectasia como síndrome requiere la presencia del signo imagenológico: dilatación bronquial. El síndrome obstructivo de la vía aérea superior es una entidad sindrómica con características propias.


Introduction: The term syndrome has been used interchangeably with disease, if it corresponds to a single nosological entity, in diagnostic discussions, and in some texts, in bronchial conditions such as acute and chronic bronchitis, bronchiectasis and especially bronchial asthma. Objective: To clarify the meaning of bronchial syndrome and its variants according to the medical diagnosis. Method: Qualitative research by means of a review of Semiology books and other texts related to the bronchial syndrome and the main conditions in which it manifests itself. Results: There is terminological ambiguity regarding bronchial syndrome and its variants, and some books do not even include them among the respiratory syndromes. In some texts, bronchial disorders are defined as syndromes while in other texts they are defined as nosological entities: acute and chronic bronchitis, bronchial asthma, and bronchiectasis. The use of bronchial syndrome is proposed, which according to the prevailing etiopathogenesis, will exhibit greater diagnostic specificity in two major sub-syndromes: the bronchitic and the obstructive bronchial. Conclusions: Bronchial syndrome expresses an affection of the bronchial tree with two major sub-syndromes of greater diagnostic specificity: the bronchitic (acute or chronic) and the obstructive bronchial (diffuse - bronchospastic or bronchostenotic - or localized). Cough and expectoration predominate in the former and dyspnea in the latter, both with hoarse, wheezing and with subcrepitant rales. To consider bronchial asthma as a syndrome or disease is a matter of focus. Defining bronchiectasis as a syndrome requires the presence of the imaging sign: bronchial dilatation. The upper airway obstructive syndrome is a syndromic entity with its own characteristics.

17.
Rev. Finlay ; 13(4)dic. 2023.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1550665

ABSTRACT

El asma bronquial sigue siendo la enfermedad crónica más frecuente en la infancia. Su prevalencia continúa aumentando a pesar de que en la actualidad se disponen de eficaces manuales terapéuticos para el correcto manejo de los principales síntomas de la enfermedad. El tratamiento no farmacológico de este padecimiento se fundamenta en tres pilares esenciales: la educación sobre la enfermedad, las guías para profesionales y pacientes y la fisioterapia respiratoria. Los pacientes que tienen un tratamiento fisioterapéutico y rehabilitador de manera habitual, tienen una mejoría significativa en el control del asma, especialmente si estos se practican bajo la supervisión de un fisioterapeuta. Los beneficios que los pacientes asmáticos logran con la fisioterapia y la rehabilitación son numerosos y uno de los efectos más importante es el impacto positivo sobre la calidad de vida.


Bronchial asthma continues to be the most common chronic disease in childhood. Its prevalence continues to increase despite the fact that effective therapeutic manuals are currently available for the correct management of the main symptoms of the disease. The non-pharmacological treatment of this condition is based on three pillars: education about the disease, guides for professionals and patients, and respiratory physiotherapy. Patients who have regular physiotherapy and rehabilitation treatment have a significant improvement in asthma control, especially if these are practiced under the supervision of a physiotherapist. The benefits that asthmatic patients achieve with physiotherapy and rehabilitation are numerous and one of the most important effects is the positive impact on quality of life.

18.
Article | IMSEAR | ID: sea-228530

ABSTRACT

Bronchogenic cysts are developmental errors of the tracheobronchial tree. Various clinical presentations from incidental detection to symptomatic presentations have been described but presenting as acute bronchial asthma is relatively rare. A 3-year-old male child repeatedly presented with acute asthmatic attacks. Initially treated as asthma and evaluated for foreign body. Contrast enhanced computed tomography (CECT) scans showed bronchogenic cyst near the left bronchus. Transthoracic excision relieved symptoms permanently. Role of CECT scan in symptomatic children with vague respiratory symptoms is being stressed. A rare case of bronchogenic cyst presenting as acute bronchial asthma is being reported. Early identification and intervention of this condition can prevent life threatening complications.

19.
Article | IMSEAR | ID: sea-226475

ABSTRACT

Growing evidence suggests that polycystic ovarian syndrome (PCOS) and Bronchial asthma coexist thanks to their common pathogenicity route. Both PCOS and Bronchial asthma has been associated with chronic low grade inflammation which results in hormonal disparity. One such case of a young woman with a medical history of Bronchial asthma presented with complaints of irregular menstrual cycle with amenorrhea and episodes of asthmatic attack once a month. The laboratory investigations including both blood and sonographic studies revealed the elevated absolute eosinophilic count, serum IgE and bilateral polycystic ovarian cyst. The Patient has been treated with internal medications and was advised to continue the physical activity such as walk for once a day and Pranayama (breathing exercise) as an adjunct to the treatment. After the treatment period of about 10 months, the outcome was assessed by both clinical prognosis as well as with USG report. The case study is about managing PCOS as well as bronchial asthma by Siddha therapeutic intervention and efficacy of the chosen drugs towards the ailments has also been explained with the help of preclinical studies conducted on the individual herbs of the formulation included in the study. This study could help to explore the therapeutic potential of Siddha medicine towards alleviating the low grade inflammation and hormonal imbalances associated with both Bronchial asthma as well as PCOS.

20.
Article | IMSEAR | ID: sea-232924

ABSTRACT

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a type of hypersensitivity reaction to mold Aspergillus fumigatus, especially common in patients with bronchial asthma. However, systemic data regarding the clinicodemographic, radiological, and immunological profiles of patients is sparse, particularly from the eastern India. Methods: This is a prospective observational study done over a year, from January 2021 to December 2021, in patients visiting the pulmonary medicine outpatient department (OPD) with symptoms similar to ABPA. Following the clinical examination, routine blood investigations, serum total immunoglobulin E (IgE) test, Aspergillus-specific IgE test, spirometry, and chest radiology (chest X-ray/high resolution CT scan) were done. ABPA was diagnosed using the 2013 ISHAM-ABPA working group criteria. Data were analyzed using statistical package for the social sciences (SPSS) software version 2021 against different categories of eosinophil count. Results: A total of 99 patients, 74 male and 25 female, were diagnosed with ABPA. The mean age±standard deviation (SD) was 37.66±15.411. Most of the patients (93) were asthmatic. Chest radiology was normal in 52.5% of the cases. The absolute eosinophil count (mean±SD) was 3963.61±5333.363. The mean±SD serum IgE and Aspergillus-specific IgE levels were 8061.07±8374.274 and 7.5826±12.693, respectively. Conclusions: There was no significant association between lung function abnormalities and eosinophil count. Serology variant (ABPA-S) was the most common finding among ABPA patients. A high eosinophil count was associated with a high incidence of bronchiectasis and hyper attenuated mucus (HAM), although the severity of bronchiectasis was not directly related to a higher peripheral eosinophil count. There may be some correlation between the peripheral eosinophil count and the total IgE but not between the peripheral eosinophil count and the Aspergillus-specific IgE.

SELECTION OF CITATIONS
SEARCH DETAIL